#USA #Upsher-Smith #Duchenne #Health Support #Maple Grove, Minnesota

New Online Resources by Upsher-Smith for the Duchenne Community

April 14, 2026 marks a significant day for families affected by Duchenne muscular dystrophy (DMD), as Upsher-Smith Laboratories, LLC, a subsidiary of Bora Pharmaceuticals, launches two dedicated online platforms aimed at supporting caregivers and healthcare professionals managing the treatment of DMD with KYMBEE™ (deflazacort) Tablets.

Understanding KYMBEE™

These tablets are specifically indicated for children aged five and older suffering from DMD, a genetic condition characterized by progressive muscle weakness. Each tablet is manufactured in the USA with components sourced from Italy, and is supported by Upsher-Smith’s Promise of Support® Program, which aims to ease the treatment journey for families navigating the complexities of this condition.

Resources for Caregivers

New Caregiver Website

The newly launched caregiver website serves as a vital resource for families, providing practical tools and guidance to streamline their experience with KYMBEE™. The site features several important elements, including:

• - Communication Guidance: Families receive tips on discussing treatment with healthcare providers, laying the groundwork for better understanding and collaboration.
• - Step-by-Step Onboarding: A user-friendly guide walks families through the process of starting treatment, ensuring clarity on what to expect once a prescription for KYMBEE™ is obtained.
• - Promise of Support® Program Details: Caregivers can access information regarding this program that facilitates connection with specialized care teams to assist with treatment management, including navigating insurance coverage and therapy continuity.
• - Supportive Community Resources: Families can download brochures and connect with reputable DMD organizations, fostering a sense of community and shared learning among those affected by this rare condition.

Support from Healthcare Professionals

The healthcare professional website complements the caregiver platform, offering clinicians streamlined access to the resources they require to initiate and maintain therapy with KYMBEE™. Key features include:

• - Prescribing Support: Clinicians can follow a detailed prescribing guide designed to simplify the initiation of KYMBEE™ therapy, thereby reducing the time and complexity often associated with starting new treatments.
• - Expert Coverage Resources: The website provides assistance with prior authorizations and appeals, addressing frequent barriers to accessing essential therapies.
• - Practice Focused Materials: Resources such as prescription forms, drug information, and FAQs are ready for clinicians to support their practice efficiently.

Upsher-Smith's mission includes not only providing medication but also enhancing the overall DMD care experience by ensuring both families and healthcare providers have the information they need when they need it.

Commitment to the DMD Community

Michelle Zachman, PharmD, Medical Affairs Director at Upsher-Smith, emphasizes the importance of these resources: "Our goal is to make the treatment journey as seamless as possible for both families and healthcare providers. The new KYMBEE™ caregiver and healthcare professional websites were built with the Duchenne community in mind—offering information, easy navigation, and practical tools that help reduce barriers, support timely access, and ensure families and clinicians have resources they need every step of the way."

The Promise of Support® Program

The comprehensive Promise of Support® Program by Upsher-Smith offers various assistance options, including:

• - Expert help with insurance navigation.
• - Copay support for eligible patients.
• - Continuous therapy supply assistance and Quick Start options.
• - 24/7 pharmacist access for personalized help.
• - Free home delivery of medication and refill reminders.

These initiatives underscore Upsher-Smith's commitment to improving the lives of DMD patients and their families. Families are encouraged to talk to their healthcare providers about KYMBEE™, while healthcare professionals can gather more information through the dedicated websites created for both audiences.

Conclusion

In sum, the launch of these resources epitomizes the proactive approach of Upsher-Smith Laboratories in addressing the unique and significant challenges faced by the Duchenne community. For more information on KYMBEE™ or to access the new resources, families can visit mykymbee.com/caregiver and healthcare professionals can visit mykymbee.com/hcp. This innovative support reflects the company's steadfast commitment to quality healthcare and accessible treatment options for pediatric patients battling DMD.